{"id":"tri-weekly-cisplatin","safety":{"boxedWarning":"Cisplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Cumulative renal toxicity may be severe. Ototoxicity may be more pronounced in children. Anaphylactic-like reactions may occur.","commonSideEffects":["Nausea and vomiting","Nephrotoxicity","Ototoxicity","Myelosuppression","Peripheral neuropathy"],"contraindications":["Pre-existing renal impairment","Hearing impairment","Myelosuppression","Hypersensitivity to cisplatin or other platinum compounds"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"DNA","explanation":"Cisplatin is a platinum coordination complex that binds to DNA, forming intrastrand and interstrand crosslinks. These DNA adducts distort the DNA helix, preventing replication and transcription, ultimately leading to cell cycle arrest and programmed cell death in cancer cells.","oneSentence":"Cisplatin forms DNA crosslinks that interfere with DNA replication and transcription, triggering apoptosis in rapidly dividing cancer cells."},"_scrapedAt":"2026-03-28T01:40:05.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122778,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"carboplatin","brand":"Paraplatin","company":"Bristol-Myers Squibb","rationale":"Alternative platinum-based chemotherapy with improved safety profile"},{"name":"oxaliplatin","brand":"Eloxatin","company":"Sanofi","rationale":"Third-generation platinum agent for solid tumors"},{"name":"weekly cisplatin","brand":null,"company":null,"rationale":"Alternative dosing schedule of same agent"}],"description":"Tri-weekly cisplatin is a dosing regimen of the platinum-based chemotherapy agent cisplatin, administered once every three weeks. This schedule is being investigated by Korea Cancer Center Hospital in phase 3 clinical trials as an alternative to weekly dosing for various cancer types.","indications":{"approved":[{"status":"investigational","condition":"Various solid tumors","patientPopulation":"Adult patients"}]},"trialDetails":[{"nctId":"NCT07092696","phase":"PHASE2","title":"Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-01","conditions":"Cervical Cancer","enrollment":34},{"nctId":"NCT07043790","phase":"NA","title":"Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-04-01","conditions":"Transitional Cell Bladder Cancer, Cystectomy, Radiation","enrollment":73},{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":3},{"nctId":"NCT02709720","phase":"PHASE2","title":"Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2016-04-15","conditions":"Lung Cancer","enrollment":68},{"nctId":"NCT02901483","phase":"PHASE1, PHASE2","title":"A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer","status":"TERMINATED","sponsor":"PharmaEngine","startDate":"2016-10-11","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT04153734","phase":"PHASE2","title":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Kobe Minimally Invasive Cancer Center","startDate":"2019-12-01","conditions":"Locally Advanced Non-small Cell Lung Cancer","enrollment":21},{"nctId":"NCT01561586","phase":"PHASE3","title":"Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-03","conditions":"Cervical Cancer","enrollment":374},{"nctId":"NCT00950261","phase":"PHASE2","title":"Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients","status":"WITHDRAWN","sponsor":"Korea Cancer Center Hospital","startDate":"2009-01","conditions":"Cervical Neoplasms","enrollment":""},{"nctId":"NCT02500940","phase":"PHASE3","title":"Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Taichung Veterans General Hospital","startDate":"2015-05","conditions":"Nasopharyngeal Carcinoma","enrollment":54},{"nctId":"NCT01097252","phase":"PHASE3","title":"Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer","status":"COMPLETED","sponsor":"Korea Cancer Center Hospital","startDate":"2002-01","conditions":"Cervical Cancers","enrollment":104},{"nctId":"NCT01999933","phase":"PHASE2, PHASE3","title":"Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer","status":"UNKNOWN","sponsor":"Mei Shi","startDate":"2013-11","conditions":"Cervical Cancer, Toxicity Due to Radiotherapy","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin"],"phase":"phase_3","status":"active","brandName":"tri-weekly cisplatin","genericName":"tri-weekly cisplatin","companyName":"Korea Cancer Center Hospital","companyId":"korea-cancer-center-hospital","firstApprovalDate":"","aiSummary":"Cisplatin is used in combination with other treatments for various types of cancer, including cervical cancer, squamous cell carcinoma of the head and neck, and lung cancer. The specific use of cisplatin in these conditions is supported by ClinicalTrials.gov, which lists it as part of interventions for these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}